Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.
Also called NCT01069692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 115 participants
- Sponsor
- Registry
-
NCT01069692 -
2008-006097-15
-
- Other papers using this trial's data
- Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- Belgium, Italy
- Registry status
- Completed
Technical summary
Registry record NCT01069692. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
- Acronym
- SBR759
- Condition
- Hyperphosphatemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- SBR759A
- Intervention (Drug)
- SBR759A
- Intervention (Drug)
- SBR759A
- Intervention (Drug)
- SBR759A
- Intervention (Drug)
- SBR759A
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01069692- Content hash
0948d17a058eb68a70078f1e2dcbd1be731ac7b6760a61af0191182919fc26d4